Mentatcurated
Longevity & Health high · independent

The cancer vaccine flips to prevention

A pancreatic-cancer vaccine has for the first time been given to people who do not have the disease, and in a 20-person trial their precancerous cysts began to shrink.

Every pancreatic-cancer vaccine tested until now was a treatment: given to patients who already had the tumour, usually after surgery, to keep it from coming back. A Johns Hopkins team led by Elizabeth Jaffee has now run the first one the other way around. They vaccinated 20 healthy people who are simply at high risk — most had a close relative with the disease, some carried a predisposing mutation, some had small precancerous cysts — to try to stop the cancer before it ever forms.

The vaccine trains the immune system against KRAS, the mutated gene that drives more than nine in ten pancreatic tumours. Crucially it is off-the-shelf: a fixed set of synthetic peptides covering the six most common KRAS mutations, not a bespoke shot manufactured per patient like the personalized mRNA vaccines in trials elsewhere. That single design choice is what makes a population-scale preventive vaccine conceivable rather than a boutique one.

Eighteen of the 20 mounted a KRAS-specific T-cell response, and the immune memory was still detectable in their blood two years later. None developed pancreatic cancer over a median 16.5 months, and among those with precancerous cysts, 37.5% saw them shrink or vanish, against 6.8% in an unvaccinated comparison group. For a cancer with a five-year survival around one in ten, catching it before it exists is close to the only way to change those odds.

The restraint matters as much as the result. This was a safety-and-immune-response readout in 20 people, not proof the vaccine prevents anything. 'None got cancer' over 16 months in a group that small is not efficacy, and the researchers say the cyst shrinkage still has to be shown to be the vaccine's doing. What has actually changed is narrower and real: the immune groundwork for intercepting pancreatic cancer in healthy people now has its first human proof, and larger prevention trials are the next thing to build.

The lenses

Novelty 4
Impact · breadth 2
Impact · depth 4
Actionable 1
Delight 3
Substance 5
Hype 3

The facts

Open aacr.org →

How this connects

Tap a node to open it

How this connects